Filing Details

Accession Number:
0001683168-21-004788
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-10-12 17:38:07
Reporting Period:
2021-10-09
Accepted Time:
2021-10-12 17:38:07
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
704562 Avid Bioservices Inc. CDMO Pharmaceutical Preparations (2834) 953698422
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1552642 R Mark Ziebell 2642 Michelle Drive, Suite 200
Tustin CA 92780
V. P., General Counsel No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock, $0.001 Par Value Acquisiton 2021-10-09 696 $0.00 14,607 No 4 M Direct
Common Stock, $0.001 Par Value Disposition 2021-10-11 349 $22.37 14,258 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Units Disposition 2021-10-09 696 $0.00 696 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
42,809 No 4 M Direct
Footnotes
  1. Each Restricted Stock Unit ("RSU") represents the contingent right to receive, upon vesting, one share of the Issuer's Common Stock.
  2. Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the RSUs listed in Table II. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the reporting person.
  3. RSUs granted to the reporting person on July 9, 2021, vest in sixteen (16) equal quarterly installments over a four (4) year period beginning October 9, 2021 and each quarter thereafter until fully-vested, subject to the reporting person's continuous service to the Issuer on such vesting dates.